GZ402671 regulatory update

FDA granted Fast Track designation to GZ/SAR402671 from Sanofi’s Genzyme Corp. company to treat Fabry’s disease. The glucosylceramide synthase (GCS) inhibitor is in a Phase IIa trial for the indicat...